الفهرس 
LymphomaOnly 14 pages are availabe for public view
 |  | from | 181 |  |  |
| | | from | 181 | | |
Abstract
Diffuse large B-cell lymphoma (DLBCL) is an aggressive Bcell lymphoma, and is very heterogeneous in genetic abnormalities,
clinical features, and response to treatment. In Egypt; DLBCL is
considered the most prevalent non-Hodgkin lymphoma (NHL)
subtype.
Etiology and risk factors are associated with age, gender,
race, ethnicity, and geography. Also, the family history of
lymphoma, exposing to some chemicals and drugs, radiation
exposure, and having a weakened immune response such as human
immunodeficiency virus (HIV), autoimmune diseases (ADs), and
certain infections such as hepatitis C virus (HCV), body weight,
and breast implant.
The development of RNA sequencing technology
represented a novel class of non-coding RNAs (ncRNAs) that are
longer than 200 nucleotides (nts), called long non-coding RNAs
(LncRNAs). The LncRNAs exhibit aberrant expression and master
regulators in various human diseases, including DLBCL.
The current study was carried out at the Medical
Biochemistry and Molecular Biology and Clinical Oncology
Departments, Faculty of Medicine, Menoufia University.
This work aimed to evaluate the serum expression levels of
the LncRNAs HOTAIR and HOTTIP in patients with DLBCL, and
also to assess their correlation with clinicopathological parameters
of DLBCL patients.